Rockwell Medical (NASDAQ:RMTI) Upgraded at Wall Street Zen

Rockwell Medical (NASDAQ:RMTI) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

A number of other research analysts have also issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $2.50 target price on shares of Rockwell Medical in a research note on Monday, January 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rockwell Medical in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $2.50.

Rockwell Medical Stock Performance

RMTI stock opened at $0.87 on Friday. Rockwell Medical has a 1 year low of $0.78 and a 1 year high of $2.10. The stock has a market capitalization of $34.29 million, a price-to-earnings ratio of -5.80 and a beta of 1.71. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.50 and a current ratio of 3.91. The stock’s fifty day moving average is $1.01 and its two-hundred day moving average is $1.05.

Rockwell Medical (NASDAQ:RMTI) last released its quarterly earnings results on Thursday, March 26th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.05). Rockwell Medical had a negative return on equity of 16.11% and a negative net margin of 7.67%.The firm had revenue of $18.35 million for the quarter, compared to the consensus estimate of $18.58 million. On average, research analysts predict that Rockwell Medical will post 0.03 EPS for the current year.

Institutional Trading of Rockwell Medical

Several institutional investors have recently modified their holdings of RMTI. Panagora Asset Management Inc. bought a new position in Rockwell Medical during the second quarter valued at about $41,000. XTX Topco Ltd grew its holdings in Rockwell Medical by 286.5% during the fourth quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock worth $52,000 after acquiring an additional 46,029 shares during the period. Jane Street Group LLC bought a new stake in Rockwell Medical in the fourth quarter worth about $84,000. GSA Capital Partners LLP raised its position in Rockwell Medical by 635.1% in the third quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock worth $197,000 after acquiring an additional 141,672 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Rockwell Medical by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock valued at $304,000 after acquiring an additional 41,668 shares during the last quarter. Institutional investors and hedge funds own 23.31% of the company’s stock.

More Rockwell Medical News

Here are the key news stories impacting Rockwell Medical this week:

• Positive Sentiment: Achieved adjusted EBITDA profitability for the second straight year, showing improved operating leverage that can support the path to sustainable profitability. Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results
• Positive Sentiment: Featured in Zacks screens as a value/momentum candidate — this can attract bargain hunters and momentum traders looking for turnaround stories. Should Value Investors Buy Rockwell Medical (RMTI) Stock?
• Neutral Sentiment: Full Q4 earnings call/transcript provides management commentary and color on drivers of the quarter and the FY26 outlook — useful for investors who want to hear management’s execution plan and assumptions. Rockwell Medical, Inc. (NASDAQ:RMTI) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 results missed revenue estimates and reported EPS came in below some consensus figures, signaling slower top‑line momentum; several outlets flagged the revenue decline as the main driver of investor concern. Rockwell Medical (RMTI) Reports Q4 Loss, Misses Revenue Estimates
• Negative Sentiment: Management’s cost‑cutting/right‑sizing plan has raised execution risk and could pressure future growth if not managed carefully — analysts flagged this as a demand/execution risk that may weigh on investor confidence. Rockwell Medical’s Cost Cuts Raise Execution Risk and Threaten Future Growth Prospects
• Negative Sentiment: Company issued a FY26 outlook that some market coverage characterized as cautious after the quarter; investors typically punish missed top‑line results and uncertain guidance more than one‑time positives. Rockwell Medical misses top-line estimates; gives FY26 outlook

About Rockwell Medical

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.